
Sign up to save your podcasts
Or


Is the standard of care for rotator cuff repair leaving patients with weak scar tissue? In this episode of the MedTech Jam Session, Mike D sits down with Brad Pratt (CEO) and Andy Carter (CTO), the co-founders of Tetrous. Brad and Andy share their extensive histories in the orthopedic space and dive deep into how Tetrous is moving beyond traditional tendon repair to actively regenerate the enthesis—the critical bone-to-tendon interface. Tetrous® has flipped the script by developing methods to enhance healing at the tendon-to-bone interface The enthesis is where failures often occur in sports medicine repairs. Tendon reattachment to the bone is a crucial clinical need, especially in larger tears, since failure rates increase linearly with tear size. In this episode, we cover:
• The Science of DBF: Why demineralized bone fibers outperform DBM powder and brittle milled fibers.
• Clinical Outcomes: Early data showing surgeon retear rates dropping from 20% to 4%, and 85% of patients returning to work/sports at 6 months.
• Capital Efficiency: How Tetrous accelerated growth (4.5x last year) by leveraging partnerships with Australian Biotechnologies and outsourcing their back office to Intech. To learn more about Tetrous, visit: Tetrous.com
By Mike Donoghue and Chris LyonsIs the standard of care for rotator cuff repair leaving patients with weak scar tissue? In this episode of the MedTech Jam Session, Mike D sits down with Brad Pratt (CEO) and Andy Carter (CTO), the co-founders of Tetrous. Brad and Andy share their extensive histories in the orthopedic space and dive deep into how Tetrous is moving beyond traditional tendon repair to actively regenerate the enthesis—the critical bone-to-tendon interface. Tetrous® has flipped the script by developing methods to enhance healing at the tendon-to-bone interface The enthesis is where failures often occur in sports medicine repairs. Tendon reattachment to the bone is a crucial clinical need, especially in larger tears, since failure rates increase linearly with tear size. In this episode, we cover:
• The Science of DBF: Why demineralized bone fibers outperform DBM powder and brittle milled fibers.
• Clinical Outcomes: Early data showing surgeon retear rates dropping from 20% to 4%, and 85% of patients returning to work/sports at 6 months.
• Capital Efficiency: How Tetrous accelerated growth (4.5x last year) by leveraging partnerships with Australian Biotechnologies and outsourcing their back office to Intech. To learn more about Tetrous, visit: Tetrous.com